IL10RB interleukin 10 receptor subunit beta
ENSG00000243646 · protein coding · Open Targets profile
Shared cell surface receptor required for the activation of five class 2 cytokines: IL10, IL22, IL26, IL28, and IFNL1. The IFNLR1/IL10RB dimer is a receptor for the cytokine ligands IFNL2 and IFNL3 and mediates their antiviral activity. The ligand/receptor complex stimulate the activation of the JAK/STAT signaling pathway leading to the expression of IFN-stimulated genes (ISG), which contribute to the antiviral state. {ECO:0000269|PubMed:12469119, ECO:0000269|PubMed:15123776}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Antibody
- GO CC high conf, UniProt SigP or TMHMM
- Other modalities
- Advanced Clinical
gnomAD loss of function constraint: o/e 0.7753300070762634 (upper bound 1.0515999794006348). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 9 registry trials, updated in the last three years, of the most advanced drugs against IL10RB (peginterferon lambda-1a, pegilodecakin, eflepedocokin alfa), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Christine M BojanowskiTulane University · 1 of 1 trials Phase 2+
- Christopher KohNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 of 1 trials Phase 2+
- David ApelianEiger BioPharmaceuticals · 1 of 1 trials Phase 2+
- Jordan FeldUniversity Health Network, Toronto · 1 of 1 trials Phase 2+
Registry trials of peginterferon lambda-1a, pegilodecakin, eflepedocokin alfa updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 7 of 9 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. Source: ClinicalTrials.gov, fetched live.
9 trials of drugs against IL10RB were stopped early; 1 give no reason
Terminated, withdrawn and suspended interventional trials of peginterferon lambda-1a, pegilodecakin, eflepedocokin alfa, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 9 most recent of 9.
- withdrawn · 2024-05-23 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · matched by the registry's drug synonyms“Study closure based on decision of the PI”
- terminated · 2023-12-21 · EVIVE Biotechnology · matched by the registry's drug synonyms“There have been significant changes in the FDA guidelines and clinical standard of care”
- withdrawn · 2023-10-02 · EVIVE Biotechnology · matched by the registry's drug synonyms“Compound development plan changed”
- terminated · 2023-06-13 · Bristol-Myers Squibb · matched by the registry's drug synonyms“Sponsor decision not based on any new unexpected safety findings or efficacy observations.”
- terminated · 2022-07-14 · Johns Hopkins University · matched by the registry's drug synonyms“Single center study with low enrollment”
- withdrawn · 2021-02-26 · Icahn School of Medicine at Mount Sinai · Peginterferon Lambda-1A“Due to the number of competing trials at their site, the study team has closed enrollment and withdrawn this trial.”
- terminated · 2021-01-20 · Eli Lilly and Company · Pegilodecakin“The CYPRESS-1 trial was closed early after the planned primary analysis because the risk benefit ratio is unfavorable.”
- terminated · 2020-09-11 · Eli Lilly and Company · Pegilodecakin“The CYPRESS-2 trial was closed early after the planned final analysis because the risk benefit ratio is unfavorable.”
- withdrawn · 2012-02-03 · Bristol-Myers Squibb · matched by the registry's drug synonymsNo reason given
Paediatric incentives and obligations for IL10RB's drugs
For peginterferon lambda-1a, pegilodecakin, eflepedocokin alfa: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · IL10RB is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-001192-PIP01-11 (peginterferon lambda-1a, Treatment of chronic hepatitis C): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 26 Jul 2012Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA EMEA-001192-PIP01-11, 2026-11-11
- EU orphan designation: yes · EU/3/19/2190 positive 21 Aug 2019: Treatment of hepatitis D virus infectionRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA EU/3/19/2190, 2026-11-11
- Authorised in the EU: no · EMA lists no centrally authorised medicine of peginterferon lambda-1a, pegilodecakin, eflepedocokin alfaRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of peginterferon lambda-1a, pegilodecakin, eflepedocokin alfaRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 1 interventional studies of peginterferon lambda-1a, pegilodecakin, eflepedocokin alfa include patients under 18; 0 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 3 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.